Ran Zheng
Director/Board Member at CARIBOU BIOSCIENCES, INC.
Net worth: - $ as of 2024-03-30
Profile
Ran Zheng is currently the Chief Executive Officer & Director at Landmark Bio PBLLC and an Independent Director at Caribou Biosciences, Inc. Previously, she worked as the Vice President-Development Supply Chain at Amgen, Inc. and as the Chief Technical Officer at Orchard Therapeutics Plc.
She received a graduate degree from the University of Minnesota and an undergraduate degree from Beijing Forestry University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-19 | 0 ( -.--% ) | - $ | 2024-03-30 |
Ran Zheng active positions
| Companies | Position | Start |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 2021-09-23 |
| Landmark Bio PBLLC | Chief Executive Officer | 2021-02-28 |
Former positions of Ran Zheng
| Companies | Position | End |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 2021-01-31 |
| AMGEN INC. | Corporate Officer/Principal | - |
Training of Ran Zheng
| University of Minnesota | Graduate Degree |
| Beijing Forestry University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
| Landmark Bio PBLLC |
- Stock Market
- Insiders
- Ran Zheng
